B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE?最新文献

Transitioning Stable Pulmonary Arterial Hypertension Patients from Parenteral Prostacyclin Therapy to Oral Selexipag 稳定期肺动脉高压患者从肠外前列环素治疗过渡到口服Selexipag

B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE? Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3824

Colin Andrew Hinkamp, S. Bartolome, F. Torres, O. Igenoza, M. Kingman, S. Harden, K. Chin, T. Shah

引用次数: 0

A Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Zamicastat, in Healthy Male Volunteers 一项双盲、随机、安慰剂对照、多次递增剂量研究，旨在研究赞密司他在健康男性志愿者中的安全性、耐受性、药代动力学和药效学特征

B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE? Pub Date : 2020-05-01 DOI: 10.1164/AJRCCM-CONFERENCE.2020.201.1_MEETINGABSTRACTS.A3816

Luís Magalhães, F. Rocha, A. Falcão, H. Gama, P. Soares-da-Silva

引用次数: 0

Initial combination therapy with macitentan and tadalafil in pulmonary arterial hypertension: a retrospective cohort study 马西坦和他达拉非联合治疗肺动脉高压:一项回顾性队列研究

B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE? Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3827

D. Marinescu, D. Christiansen, J. Thenganatt, J. Granton

{"title":"Initial combination therapy with macitentan and tadalafil in pulmonary arterial hypertension: a retrospective cohort study","authors":"D. Marinescu, D. Christiansen, J. Thenganatt, J. Granton","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3827","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3827","url":null,"abstract":"\u0000 Purpose: Initial combination therapy with ambrisentan and tadalafil has been demonstrated superior to either agent alone in pulmonary arterial hypertension (PAH). More recently, the OPTIMA trial showed efficacy of another combination of endothelin receptor antagonist and phosphodiesterase 5-inhibitor, macitentan and tadalafil, as initial therapy for PAH. The objective of this study was to assess the effectiveness, tolerability, and safety of macitentan and tadalafil in a real-world clinical setting.Methods: This single centre, retrospective cohort study identified adult patients newly diagnosed with PAH between January 2014 and December 2017 who were started on macitentan and tadalafil. Patients were retrospectively followed for one year. Effectiveness was evaluated via change from baseline in disease risk profile based on a validated score incorporating World Health Organization functional class, 6-minute walk distance (6MWD), B-type natriuretic peptide (BNP), and hemodynamics on follow-up right heart catheterization. Secondary endpoints included change in 6MWD, BNP, and hemodynamic variables. Drug tolerability and adverse events were assessed.Results: The cohort included 46 patients, 8 of whom (17%) did not tolerate and discontinued either macitentan or tadalafil. Median time to follow-up was 161 days (IQR 72). 42% of patients with an initially moderate or high risk disease profile improved to low risk. Secondary endpoints showed a reduction in the geometric mean of pulmonary vascular resistance of 45% (95% CI 29, 57%) and improvement in 6MWD of 88m (95% CI 27, 148m).Conclusion: In a real-world setting, macitentan and tadalafil as initial combination therapy for PAH was well tolerated and yielded clinical benefit.","PeriodicalId":145388,"journal":{"name":"B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE?","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124300641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Impact of Targeted Pulmonary Arterial Hypertension Therapy in Patients with Combined Pre- and Post-Capillary Pulmonary Hypertension 靶向肺动脉高压治疗对合并毛细血管前和后肺动脉高压患者的影响

B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE? Pub Date : 2020-03-01 DOI: 10.1016/s0735-1097(20)32721-2

N. Moghaddam, J. Swiston, M. Tsang, L. Lee, N. Brunner

引用次数: 2